Drug intelligence / Profile preview

mGlu2 negative allosteric modulator (Camino Pharma)

Development stage: Preclinical
Lead developer: Camino Pharma
Modality: Small Molecules
Administration: Oral

Overview

Camino Pharma is developing a small molecule negative allosteric modulator (NAM) targeting the metabotropic glutamate receptor 2 (mGlu2) for the treatment of treatment-resistant depression. The mechanism of action is designed to mimic the rapid-acting antidepressant effects of ketamine by modulating glutamatergic neurotransmission, specifically by reducing the inhibitory effect of mGlu2 autoreceptors to increase glutamate release in the prefrontal cortex. This approach aims to provide the therapeutic benefits of ketamine without its associated dissociative, psychotomimetic, or addictive side effects. The program is currently in the discovery and preclinical stages of development.

Other names: Camino International mGlu2 NAMmGlu2 NAM (Camino Pharma)Unnamed mGlu2 NAM (depression)

Targets

GRM2 (mGluR2)

Beyond the preview

Go deeper on mGlu2 negative allosteric modulator (Camino Pharma).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mGlu2 negative allosteric modulator (Camino Pharma).

Explore the full profile